Abstract
Purpose
Diabetes is a suspected risk factor for pancreatic cancer, but questions remain about whether it is a risk factor or a result of the disease. This study prospectively examined the association between diabetes and the risk of pancreatic adenocarcinoma in pooled data from the NCI pancreatic cancer cohort consortium (PanScan).
Methods
The pooled data included 1,621 pancreatic adenocarcinoma cases and 1,719 matched controls from twelve cohorts using a nested case–control study design. Subjects who were diagnosed with diabetes near the time (<2 years) of pancreatic cancer diagnosis were excluded from all analyses. All analyses were adjusted for age, race, gender, study, alcohol use, smoking, BMI, and family history of pancreatic cancer.
Results
Self-reported diabetes was associated with a forty percent increased risk of pancreatic cancer (OR = 1.40, 95 % CI: 1.07, 1.84). The association differed by duration of diabetes; risk was highest for those with a duration of 2–8 years (OR = 1.79, 95 % CI: 1.25, 2.55); there was no association for those with 9+ years of diabetes (OR = 1.02, 95 % CI: 0.68, 1.52).
Conclusions
These findings provide support for a relationship between diabetes and pancreatic cancer risk. The absence of association in those with the longest duration of diabetes may reflect hypoinsulinemia and warrants further investigation.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 2012:6210–6229
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
Raimondi S, Maisonneuve P, Lowenfels AB (2009) Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6(12):699–708
Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P et al (2009) Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 170(4):403–413
Jacobs EJ, Chanock SJ, Fuchs CS, LaCroix A, McWilliams RR, Steplowski E et al (2010) Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 127(6):1421–1428
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41(9):986–990
Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res 70(3):1015–1023
Wolpin BM, Kraft P, Xu M, Steplowski E, Olsson ML, Arslan AA et al (2010) Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the Pancreatic Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 19(12):3140–3149
Arslan AA, Helzlsouer KJ, Kooperberg C, Shu X-O, Steplowski E, Bueno-de-Mesquita HB et al (2010) Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 170(9):791–802
Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, Michaud DS, Severinsen MT, Overvad K et al (2010) Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 126(10):2394–2403
DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14(3):173–194
Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S et al (2011) The complexities of obesity, diabetes, and the development and progression of pancreatic cancer. Biochim Biophys Acta 1885(2):135–146
Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M et al (2008) Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterol 134(1):95–101
Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273(20):1605–1609
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076–2083
The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4:1–10
Gallicchio L, Chang H, Christo D, Thuita L, Huang H, Strickland P et al (2008) Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland. Am J Epidemiol 167:807–813
Calle E, Rodriguez C, Jacobs E, Almon M, Chao A, McCullough M et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design and baseline characteristics. Cancer 94:2490–2501
Riboli E, Hunt K, Slimani N, Ferrari P, Norat T, Fahey M et al (2002) European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE et al (2007) Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67(16):7923–7928
McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, Andrade Md, Boardman LA et al (2008) Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res 68(12):4928–4935
Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I et al (2005) Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. Int J Cancer 114(2):323–327
Hayes RB, Sigurdson A, Moore L, Peters U, Huang W-Y, Pinsky P et al (2005) Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 592(1–2):147–154
Xu W-H, Zhang X-L, Gao Y-T, Xiang Y-B, Gao L-F, Zheng W et al (2007) Joint effect of cigarette smoking and alcohol consumption on mortality. Prev Med 45(4):313–319
Zheng W, Chow W-H, Yang G, Jin F, Rothman N, Blair A et al (2005) The Shanghai Women’s Health study: rationale, study design, and baseline characteristics. Am J Epidemiol 162(11):1123–1131
Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al (2003) Implementation of the women’s health initiative study design. Ann Epidemiol 13(9 Suppl 1):S5–S17
Rexrode K, Lee I, Cook N, Hennekens C, Buring J (2000) Baseline characteristics of participants in the Women’s Health Study. J Womens Health Gend Based Med 9(1):19–27
Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey J-N, Pisters PW et al (2007) Risk factors for pancreatic cancer: case–control study. Am J Gastroenterol 102(12):2696–2707
Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ (2009) Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 15(42):5274–5278
Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21(6):879–887
Li D, Abbruzzese J (2010) New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 16(17):4313–4318
Batty G, Kivimaki M, Morrison D, Huxley R, Smith G, Clarke R et al (2009) Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev 18(2):673–675
Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15(6):548–555
Ammon HPT (1997) Hyper- and hypoinsulinemia in type-2 diabetes: what may be wrong in the secretory mechanism of the B-cell. Exp Clin Endocrinol Diabetes 105(S02):43,7
Gapstur SM, Liu K, Gann PH, Dyer A (2000) Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283(19):2595–2596
Batty GD, Shipley MJ, Marmot M, Smith GD (2004) Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 15(9):873–881
Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE et al (2007) Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16(10):2101–2109
Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30(3):561–567
Grote V, Becker S, Kaaks R (2010) Diabetes mellitus type 2: an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118(1):4–8
Grote V, Rohrmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J et al (2011) Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 54(12):3037–3046
Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22):2872–2878
Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterol 137(2):482–488
McFarland MS, Cripps R (2010) Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 30(11):1159–1178
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterol 134(4):981–987
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117
World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR
Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562
Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE et al (2011) A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 129(7):1708–1717
Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta, GA
National Institute of Diabetes and Digestive and Kidney Diseases (2008) National Diabetes Statistics, 2007 fact sheet. National Institutes of Health, Bethesda, MD
Acknowledgments
The authors thank the investigators from the PanScan Cohort Consortium centers and the study participants, without whom this study would have not been possible. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Trial was supported by funding provided by the Intramural Research Program of the National Cancer Institute, and the U.S. Public Health Service contracts [(N01-CN-45165, N01-RC-45035, N01-RC-37004]. CLUE II was supported by National Institute of Aging [5U01AG018033] and National Cancer Institute [CA105069, CA73790]. European Prospective Investigation into Cancer and Nutrition was supported by the European Commission: Public Health and Consumer Protection Directorate 1993–2004; Research Directorate-General 2005; Ligue contre le Cancer; Societé 3 M; Mutuelle Générale de l’Education Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center, Federal Ministry of Education and Research (Germany); Danish Cancer Society (Denmark); Health Research Fund (FIS) of the Spanish Ministry of Health, The participating regional governments and institutions (Spain); Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, the Wellcome Trust (United Kingdom); Greek Ministry of Health and Social Solidarity, Hellenic Health Foundation and Stavros Niarchos Foundation (Greece); Italian Association for Research on Cancer (AIRC) (Italy); Dutch Ministry of Public Health, Welfare and Sports, Dutch Prevention Funds, LK Research Funds, Dutch ZON (Zorg Onderzoek Nederland) (the Netherlands); Swedish Cancer Society, Swedish Scientific Council, Regional Government of Skane and Västerbotten (Sweden); World Cancer Research Fund (WCRF). The New York University Women’s Health Study is supported by the National Cancer Institute research grants [R01CA034588, R01CA098661, P30CA016087] and the National Institute of Environmental Health Sciences Center grant [ES000260]. The Nurses’ Health Study is supported by the National Cancer Institute research grants P01CA087969 and R01CA124908. The Health Professional’s Follow-up Study is supported by P01CA055075 and R01CA124908. The Physician’s Health Study by R01CA097193 and R01CA124908. The Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial was supported by contracts from the National Cancer Institute [University of Colorado Denver, NO1-CN-25514, Georgetown University NO1-CN-25522, Pacific Health Research Institute NO1-CN-25515, Henry Ford Health System NO1-CN-25512, University of Minnesota, NO1-CN-25513, Washington University NO1-CN-25516, University of Pittsburgh NO1-CN-25511, University of Utah NO1-CN-25524 Marshfield Clinic Research Foundation NO1-CN-25518, University of Alabama at Birmingham NO1-CN-75022, Westat, Inc. NO1-CN-25476, University of California, Los Angeles NO1-CN-25404]. The PLCO Study is sponsored by National Cancer Institute’s Division of Cancer Prevention, in collaboration with the Division of Cancer Epidemiology and Genetics. The Shanghai Men’s and Women’s Health Studies were supported by the National Cancer Institute extramural research grants [R01CA82729, R01CA70867, R01CA124908] and by the Intramural Research Program of National Cancer Institute (Division of Cancer Epidemiology and Genetics). The Women’s Health Initiative is funded by the National Heart, Lung, and Blood Institute through contracts [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221]. Role of the Sponsors: This project has been funded with federal funds from the National Cancer Institute, National Institutes of Health. The funding agency had no role in the conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Additional information
Laufey Amundadottir, Alan A. Arslan, H. Bas Bueno-de-Mesquita, Eric J. Duell, Charles S. Fuchs, Myron Gross, Kathy Helzlsouer, Eric J. Jacobs, Charles Kooperberg, Andrea LaCroix, Gloria Petersen, Rachael Z. Stolzenberg-Solomon, Kala Visvanathan, Brian M. Wolpin, Wei Zheng: Steering committee members.
Rights and permissions
About this article
Cite this article
Elena, J.W., Steplowski, E., Yu, K. et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24, 13–25 (2013). https://doi.org/10.1007/s10552-012-0078-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-012-0078-8